• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

State of the Science: The role of HIPEC in the treatment of ovarian cancer.

作者信息

Dellinger Thanh H, Han Ernest S

机构信息

Department of Surgery, Division of Gynecologic Oncology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, United States of America.

Department of Surgery, Division of Gynecologic Oncology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, United States of America.

出版信息

Gynecol Oncol. 2021 Feb;160(2):364-368. doi: 10.1016/j.ygyno.2020.12.029. Epub 2021 Jan 6.

DOI:10.1016/j.ygyno.2020.12.029
PMID:33419611
Abstract
摘要

相似文献

1
State of the Science: The role of HIPEC in the treatment of ovarian cancer.科学现状：腹腔热灌注化疗在卵巢癌治疗中的作用
Gynecol Oncol. 2021 Feb;160(2):364-368. doi: 10.1016/j.ygyno.2020.12.029. Epub 2021 Jan 6.
2
Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.美国卵巢癌腹腔内热化疗（HIPEC）的现状。
Gynecol Oncol. 2020 Dec;159(3):681-686. doi: 10.1016/j.ygyno.2020.09.022. Epub 2020 Sep 22.
3
HIPEC improves survival in stage III epithelial ovarian cancer.腹腔热灌注化疗可提高Ⅲ期上皮性卵巢癌患者的生存率。
Lancet Oncol. 2018 Mar;19(3):e138. doi: 10.1016/S1470-2045(18)30065-2. Epub 2018 Jan 26.
4
Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.卵巢癌随机 III 期开放标签 OVHIPEC-1 试验的中心放射学评估。
Int J Gynecol Cancer. 2020 Dec;30(12):1928-1934. doi: 10.1136/ijgc-2020-001825. Epub 2020 Oct 12.
5
Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a systematic review and updated meta-analysis.减瘤手术联合腹腔热灌注化疗治疗上皮性卵巢癌的疗效和安全性：一项系统评价与更新的荟萃分析
J Egypt Natl Canc Inst. 2025 Apr 30;37(1):28. doi: 10.1186/s43046-025-00286-y.
6
Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.新辅助化疗后间隔细胞减灭术和 HIPEC 治疗原发性晚期 IIIC/IVA 上皮性卵巢癌的复发模式。
Eur J Surg Oncol. 2021 Jun;47(6):1427-1433. doi: 10.1016/j.ejso.2021.01.013. Epub 2021 Jan 22.
7
Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.腹腔内热灌注化疗在晚期上皮性卵巢癌间隔肿瘤细胞减灭术中的应用：单中心真实世界经验。
Cancer. 2020 Dec 15;126(24):5256-5262. doi: 10.1002/cncr.33167. Epub 2020 Sep 15.
8
Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.热腹腔内化疗（HIPEC）在原发性卵巢癌的治疗中具有成本效益。
Gynecol Oncol. 2018 Oct;151(1):4-5. doi: 10.1016/j.ygyno.2018.07.019. Epub 2018 Jul 30.
9
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.热灌注腹腔化疗治疗复发性卵巢癌（CHIPOR）：一项随机、开放标签的3期试验。
Lancet Oncol. 2024 Dec;25(12):1551-1562. doi: 10.1016/S1470-2045(24)00531-X. Epub 2024 Nov 14.
10
A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer: a rationale and study design of the KOV-HIPEC-02 trial.一项关于减瘤手术联合热灌注腹腔化疗治疗铂耐药复发性卵巢癌的随机、多中心、开放标签III期试验：KOV-HIPEC-02试验的理论依据和研究设计
Int J Gynecol Cancer. 2025 Apr;35(4):101630. doi: 10.1016/j.ijgc.2025.101630. Epub 2025 Jan 9.

引用本文的文献

1
Small bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery.小肠梗阻与卵巢癌：来自一项倾向评分匹配研究的见解，该研究针对减瘤手术后接受和未接受腹腔热灌注化疗的患者
World J Surg Oncol. 2025 Aug 26;23(1):318. doi: 10.1186/s12957-025-03968-y.
2
Combined Hyperthermic Intraperitoneal Chemotherapy and Normothermic Intraperitoneal Chemotherapy Long-Term After Interval Cytoreduction in Ovarian Cancer: A Phase I Clinical Trial (BICOV1).卵巢癌间隔肿瘤细胞减灭术后长期联合热灌注腹腔化疗与常温腹腔化疗：一项I期临床试验（BICOV1）
Cancers (Basel). 2025 Jun 12;17(12):1957. doi: 10.3390/cancers17121957.
3
Evaluating the Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Interval and Secondary Debulking in Ovarian Cancer: A Systematic Review.
评估腹腔热灌注化疗（HIPEC）对卵巢癌无瘤间期和二次肿瘤细胞减灭术的影响：一项系统评价
Cancers (Basel). 2025 Mar 6;17(5):904. doi: 10.3390/cancers17050904.
4
Hyperthermia Intensifies α-Mangostin and Synthetic Xanthones' Antimalignancy Properties.高热增强 α-倒捻子素和合成紫檀芪的抗恶性肿瘤特性。
Int J Mol Sci. 2024 Aug 15;25(16):8874. doi: 10.3390/ijms25168874.
5
The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential.环状RNA在卵巢癌顺铂耐药中的新作用：从分子机制到未来潜力
Noncoding RNA Res. 2024 May 20;9(4):1280-1291. doi: 10.1016/j.ncrna.2024.05.005. eCollection 2024 Dec.
6
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.范式转变：先进时代卵巢癌管理的全面综述。
Int J Mol Sci. 2024 Feb 3;25(3):1845. doi: 10.3390/ijms25031845.
7
Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis.胃癌腹膜转移局限患者减瘤手术及腹腔热灌注化疗的早期成本效益分析
Pharmacoecon Open. 2024 Jan;8(1):119-131. doi: 10.1007/s41669-023-00454-7. Epub 2023 Nov 30.
8
The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy.高热腹腔内化疗在子宫癌治疗中的作用。
Int J Mol Sci. 2023 Aug 2;24(15):12353. doi: 10.3390/ijms241512353.
9
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.腹腔内热灌注化疗治疗卵巢癌。
Ann Surg Oncol. 2023 Sep;30(9):5597-5609. doi: 10.1245/s10434-023-13757-0. Epub 2023 Jun 26.
10
Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.腹腔内热灌注化疗（HIPEC）：对上皮性卵巢癌的分子和细胞作用机制及作用效果的概述。
Int J Mol Sci. 2022 Sep 3;23(17):10078. doi: 10.3390/ijms231710078.